Strategies to Mitigate Adverse Events with Asparaginase Treatment in Patients With ALL

Download this slideset from a live CCO symposium for an expert overview on identifying and managing adverse events associated with asparaginase-based therapy in patients with ALL, including discussion of hepatotoxicity, thrombosis, pancreatitis, hypertriglyceridemia, and factors contributing to their development.
Wendy Stock, MD
Program Director
Emily Curran, MD
Dan Douer, MD
person default
Scott Howard, MD, MSc
person default
Stephen P. Hunger, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 3.36 MB
Released: December 15, 2021


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Jazz Pharmaceuticals
Servier Pharmaceuticals
Servier Oncology Global Medical and Patient Affairs

Related Content

Downloadable slideset with highlights from key hematologic cancers as presented at EHA 2022 Congress, from Clinical Care Options (CCO)

Stéphane de Botton, MD Jesús F. San-Miguel, MD, PhD Alessandra Tedeschi, MD Released: June 30, 2022

Experts discuss important new data from ASCO 2022 that may impact treatment for chronic lymphocytic leukemia and mantle cell lymphoma, from Clinical Care Options (CCO)

Brad S. Kahl, MD Anthony Mato, MD, MSCE Released: June 30, 2022

From Clinical Care Options (CCO), download slides reviewing the integration of CAR T-cell therapy into community care

Jesús G. Berdeja, MD Caron A. Jacobson, MD Released: June 30, 2022

Slides from Clinical Care Options (CCO) with key findings on BTK inhibitors in CLL and MCL from the 2022 ASCO, EHA, Pan Pacific, ESMO, and SOHO meetings

Released: June 27, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings